Abstract
We evaluated the reliability of very low serum thyroglobulin (Tg) levels (< 3 ng/ml) obtained after withdrawal of thyroid suppression therapy in 224 patients without anti-Tg antibodies, who had undergone total thyroidectomy (125 patients) or thyroidectomy followed by 1 or more courses of131I therapy (99 patients), by performing whole body scans after a therapeutic course of131I given at the same time of Tg measurement. In 79 patients (35%) a positive scan, associated with a very low level of Tg, was noted. The 1311 uptake was limited to the thyroid bed in 60 patients, but metastases were demonstrated in 19 patients (8.5%). These results are mainly explained by the much improved performance of scintigraphy after administration of therapeutic doses of131I. In the majority of patients, especially those whose131I uptake was limited to the thyroid bed, further scans were negative. Therefore, in these cases, negative Tg values can generally be considered an early indication of satisfactory evolution. However, in 8.5% of all cases, very low Tg levels were associated with metastases. Thus the follow up of thyroid cancer should not rely only upon Tg determination, even after suppression therapy withdrawal.
Similar content being viewed by others
References
Arning G, Ehrenheim C, Schober O, Hundeshagen H (1987)131I-speichernde pulmonale und ossäre Metastasen differenzierter Schilddrüsenkarzinome bei niedrigem. Serum-Thyreoglobulinspiegel-Ausnahme in der Tumornachsorge? Nuklearmedizin 26:139–142
Aschcraft MW, Van Herle AJ (1981) The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer. Am J Med 71:806–814
Blahd WH, Drickman MV, Proter CW, Hill VA, Baumgartner WA (1984) Serum thyroglobulin, a monitor of differentiated thyroid carcinoma in patients receiving thyroid hormone suppression therapy: Concise communication. J Nucl Med 25:673–676
Botsch H, Schultz E, Lochner B (1979) Serum-Thyreoglobulinbestimmung zur Verlaufskontrolle bei Schilddrüsenkarzinom-Patienten. Dtsch Med Wschr 104:1072–1074
Coakley AJ, Page CJ, Croft D (1980) Scanning dose and detection of thyroid metastases. J Nucl Med 21:803–807
Dralle H, Schwarzrock R, Lang W (1985) Comparison of histology and immuno-histochemistry with thyroglobulin serum levels and radioiodine uptake in recurrences and metastases of differentiated thyroid carcinomas. Acta Endocrinol 108:504–510
Echenique RL, Kasi L, Haynie TP, Glenn HJ, Samaan NA, Hill CS (1982) Critical evaluation of serum thyroglobulin levels and I-131 scans in post therapy patients with differentiated thyroid carcinoma: Concise communication. J Nucl Med 23:235–240
Feldt RU, Schlumberger (1988) European interlaboratory comparison of serum thyroglobulin measurement. J Endocrinol Invest 11:175–181
Freitas JE, Gross MD, Ripley S, Shapiro B (1985) Radionuclide diagnosis and therapy of thyroid cancer: Current status report. Sem Nucl Med 15:106–131
Lefort G, Lanet MJ, Ducassou D, Latapie JL (1981) Dosage de la thyroglobuline sérique. Bordeaux Méd 14:1257–1259
Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, Pinchera A (1987) Therapeutic doses of Iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 28:1888–1891
Ramanna L, Waxman AD, Brachman MB, Sensel N, Tanasescu D, Berman DS, Catz B, Braunstein GD (1985) Correlation of thyroglobulin measurements and radioiodine scans in the follow-up of patients with differentiated thyroid cancer. Cancer 55:1525–1530
Ramos-Gabatin A, Girard C, Reasner C (1987) Thyroglobulin (Tg) levels and I-131 total body scan (TBS) in follow-up of patients with differentiated thyroid carcinoma. J Nucl Med 28:685 (Abstr)
Reiners C, Reimann J, Shäffer R (1984) Das metastasierende differenzierte Schilddrüsenkarzinom. Fortsch Röntgenstr 141:306–313
Salabe GB, Fontana S, Andreoli M (1972) Radio-immunoassay for human antithyroglobulin antibodies. Hormones 3:1–13
Schatz H, Grebe SF, Mäser E (1982) Serum Thyreoglobulinspiegel als Tumor-marker bei Schilddrüsenkarzinoms. Klin Wschr 60:457–464
Schlumberger M, Charbord P, Fragu P, Lumbroso J, Parmentier C, Tubiana M (1980) Circulating thyroglobulin and thyroid hormones in patients with metastases of differentiated thyroid carcinoma: Relationship to serum thyroglobulin levels. J Clin Endocrinol Metab 51:513–519
Schlumberger M, de Vathaire F, Guermazi F, Fragu P, Parmentier C (1985) Thyroglobulin measurement during the follow-up of patients with thyroid remnants. In: Jaffiol C, Milhaud G (eds) Thyroid cancer. Excerpta Medica, Amsterdam New York, pp 273–277
Schlumberger M, Tubiana M, de Vathaire F, Hill C, Gardet P, Travagli JP, Fragu P, Lumbroso J, Caillou B, Parmentier C (1986) Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 63:960–967
Van Herle AJ, Van Herle IS, Greipel MA (1985) An international cooperative study evaluating serum thyroglobulin standards. J Clin Endocrinol Metab 60:338–343
Van Herle AJ, Uller RP (1975) Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas. J Clin Invest 56:272–277
Van Herle AJ, Uller RP, Matthews ML, Brown J (1973) Radioimmunoassay for measurement of thyroglobulin in human serum. J Clin Invest 52:1320–1327
Van Herle AJ (1985) Serum thyroglobulin: its diagnostic and prognostic value in patients with thyroid cancer. In: Jaffiol C, Milhaud G (eds) Thyroid cancer. Excerpta Medica, Amsterdam New York, pp 237–244
Waxman A, Ramanna L, Chapman N, Brachman M, Tanasescu D, Berman D, Catz B, Braustein G (1981) The significance of131I scan dose in patients with thyroid cancer: determination of ablation: Concise communication. J Nucl Med 22:861–865
Author information
Authors and Affiliations
Additional information
Presented in part as an oral communication at the European Nuclear Medicine Congress, Budapest, Hungary, 1987
Rights and permissions
About this article
Cite this article
Brendel, A.J., Lambert, B., Guyot, M. et al. Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma. Eur J Nucl Med 16, 35–38 (1990). https://doi.org/10.1007/BF01566010
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01566010